Prospective randomized multicenter study for evaluation of supportive effects of the biological response modifier. Factor AF2 in advanced urothelial cancer;Bewertung des komplementärtherapeutikums factor AF2 als supportivum in der behandlung des fortgeschrittenen urothelkarzinoms. Prospektiv randomisierte multicenterstudie

Urologe - Ausgabe A

Volumn 41, Issue 2, 2002, Pages 164-168

  Krege, S ^a   Hinke, A ^b   Otto, T ^a   Rubben H ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Wissenschaftlicher Service Pharma   (Germany)

Author keywords

Advanced urothelial cancer; Biological response modifier; Chemotherapy; Factor AF2

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL RESPONSE MODIFIER; CISPLATIN; FACTOR AF2; METHOTREXATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG RESPONSE; EVALUATION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; TIME; UROGENITAL TRACT CANCER;

EID: 0036933238     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001200100129     Document Type: Article

References (15)

1. Baier JE, Neumann HA, Gallati H, Ricken D (1991) Improvement of impaired mitogen-induced interferon-gamma release of peripheral blood mononuclear cells derived from tumor patients by Factor AF2. Res Exp Med 191: 281-289
2. Cramer R, Dri P, Spessotto P, Mittenzwei H, Patriarca P (1993) Potentiation of human polymorphonuclear leukocytes respiratory burst and phagocytosis by a standardized liver and spleen fraction of peptides. Drug Res 43:686-689
3. Dingermann T (Hrsg) (2000) Transparenzkriterien für pflanzliche, homöopathische und anthroposophische Arzneimittel. Karger, Basel
4. Giani AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A, Bonadonna G (1989) Granulocytemacrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet II: 580-585
5. Ivanov VI, Turdyev AA, Aleksandrova IA, Svidovaya LV, Rodina EA (1987) Liver microsomal lipids of mice irradiated and administered an extract turtle spleen. Radiobiologiia 27:257-264
6. Kindler M (1997) Factor AF2 als Begleitmaßnahme zur Chemotherapie - myeloprotektive und antiemetische Wirkung. J Oncol 29: 7-10
7. Lange OF (1987) Supportive Therapie mit xenogenen Peptiden bei Patienten mit metastasiertem Mammakarzinom unter aggressiver Chemotherapie (modifiziertes AC-Schema), eine prospektive randomisierte Doppelblind-studie. Onkologie 10 (Suppl): 40-43
8. Leder GH, Fiebig HH, Widmer KH, Arnold H (1986) Colony inhibition of human tumor xenografts in vitro by Factor AF2. J Cancer Res Clin Oncol 111: 49
9. Leder GH, Leder O (1990) Morphological studies on the subchronic toxicity of a standardized liver- and spleen-extract. Drug Res 40: 187-189
10. Loehrer PJ, Einhorn LH, Elson PJ et al. (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group Study. J Clin Oncol 10: 1066-1073
11. Meyers FJ, Blumenstein B, Crawford ED et al. (1992) Combination of cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group Study. J Urol 148: 52-54
12. Ozer H (1996) American Society of Clinical Oncology guidelines for the use of hematopoietic colony-stimulating factors. Curr Opin Hematol 3: 3-10
13. Papadopoulos I, Wand H (1989) Prüfung der Wirksamkeit von Factor AF2 auf die verbesserte Verträglichkeit des PE-Schemas (Epirubicin/Cisplatin) beim metastasierten Prostatakarzinom. Onkologie 12:26-31
14. Sternberg CN, Yagoda A, Scher HI et al. (1989) Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64: 2448-2458
15. Wagner H, Röllinghoff M (1973) Cell-mediated immunity in vitro against syngeneic mouse plasma tumor cells. Nature 291: 53-54